retatrutide risks VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide vs Ozempic: Clinical Trial
Description
To qualify, patients must meet one of the following: BMI of 35 or higher BMI of 30 or higher with heart failure, uncontrolled hypertension on two medications, or chronic kidney disease stage 3a or above BMI of 27 or higher with a history of pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease That is a meaningfully different population than a standard cash-pay weight loss patient
Conversely, participants who were given a placebo (only diet and exercise) showed an average weight reduction between 0.2 and 3.0 kg
95% CI 0.71 to 0.98) Adverse Events Serious adverse events were reported in 13.3% of Semaglutide and 26.7% in the placebo group
11 , e0215921 (2023)
Most people notice their appetite change within days
He has a strong track record of treating and co-managing individuals with chronic illnesses
